DDInter1139 DDInter649
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.
Mefenamic acid {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Mefenamic acid {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Enzalutamide
Mefenamic acid {u} (Compound) resembles {v} (Compound) Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Mefenamic acid {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nilutamide
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Mefenamic acid {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Nilutamide
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Mefenamic acid {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Bicalutamide
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Mefenamic acid {u} (Compound) causes {v} (Side Effect) Vertigo
Vertigo {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Mefenamic acid {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Alvimopan
Alvimopan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Mefenamic acid {u} (Compound) resembles {v} (Compound) Diclofenac
Diclofenac {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Mefenamic acid {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Bicalutamide
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Mefenamic acid (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Enzalutamide (Compound)
Mefenamic acid (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Mefenamic acid (Compound) resembles Diclofenac (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Mefenamic acid (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilutamide (Compound) and Nilutamide (Compound) resembles Enzalutamide (Compound)
Mefenamic acid (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Nilutamide (Compound) and Nilutamide (Compound) resembles Enzalutamide (Compound)
Mefenamic acid (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Bicalutamide (Compound) and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Mefenamic acid (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Mefenamic acid (Compound) resembles Ketoprofen (Compound) and Ketoprofen (Compound) resembles Alvimopan (Compound) and Alvimopan may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Mefenamic acid (Compound) resembles Diclofenac (Compound) and Diclofenac (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Mefenamic acid (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bicalutamide (Compound) and Bicalutamide (Compound) resembles Enzalutamide (Compound)